GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (WBO:ABC) » Definitions » EBIT

Cencora (WBO:ABC) EBIT : €1,952 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cencora EBIT?

Cencora's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was €651 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was €1,952 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cencora's annualized ROC % for the quarter that ended in Dec. 2024 was 12.81%. Cencora's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 131.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cencora's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 3.73%.


Cencora EBIT Historical Data

The historical data trend for Cencora's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cencora EBIT Chart

Cencora Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,377.40 2,036.54 2,417.67 2,282.99 2,029.64

Cencora Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 772.13 500.37 638.47 161.73 650.96

Competitive Comparison of Cencora's EBIT

For the Medical Distribution subindustry, Cencora's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cencora's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cencora's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cencora's EV-to-EBIT falls into.



Cencora EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,952 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cencora  (WBO:ABC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cencora's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=3084.616 * ( 1 - 20.43% )/( (17984.126 + 20323.266)/ 2 )
=2454.4289512/19153.696
=12.81 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=60458.602 - 48384.351 - ( 2822.516 - max(0, 48903.625 - 42993.75+2822.516))
=17984.126

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=65946.87 - 49942.564 - ( 3079.168 - max(0, 52056.195 - 47737.235+3079.168))
=20323.266

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cencora's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2603.82/( ( (1965.45 + max(-8292.612, 0)) + (2005.297 + max(-5284.497, 0)) )/ 2 )
=2603.82/( ( 1965.45 + 2005.297 )/ 2 )
=2603.82/1985.3735
=131.15 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(21508.505 + 17117.949 + 1465.285) - (48384.351 + 0 + 0)
=-8292.612

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(23441.166 + 19585.159 + 1631.742) - (49942.564 + 0 + 0)
=-5284.497

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cencora's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=1951.522/52380.135
=3.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cencora EBIT Related Terms

Thank you for viewing the detailed overview of Cencora's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cencora Business Description

Address
1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Cencora Headlines

No Headlines